Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

Fig. 3

Survival analysis to evaluate the association between EPHA5 mutation and overall survival in patients in different treatment groups from OAK and POPLAR cohorts(P = 0.0186) (A). Survival difference between patients receiving atezolizumab and docetaxel stratified with EPHA5 mutation status (P = 0.6816 and P < 0.0001 respectively) (B and C). Subgroup survival of different variables including EPHA5 mutation status and metastatic sites number was plotted and presented on forest plot after multivariate Cox proportional hazard analysis (D and E). HR: hazard ratio

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us